EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

European Urology

Volumn 71, Issue 3, 2017, Pages 447-461

  Babjuk, Marko ^a   Böhle, Andreas ^b   Burger, Maximilian ^c   Capoun, Otakar ^d   Cohen, Daniel ^e,f   Compérat, Eva M ^g   Hernández, Virginia ^h   Kaasinen, Eero ⁱ   Palou, Joan ^j   Rouprêt, Morgan ^g,k   van Rhijn, Bas W G ^l   Shariat, Shahrokh F ^m   Soukup, Viktor ^d   Sylvester, Richard J ⁿ   Zigeuner, Richard ^o  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b HELIOS AGNES KARLL HOSPITAL   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d CHARLES UNIVERSITY   (Czech Republic)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MOUNT VERNON CANCER CENTRE   (United Kingdom)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

ⁱ HYVINKÄÄ HOSPITAL   (Finland)

^j UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^k SORBONNE UNIVERSITÉ   (France)

^l ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ European Association of Urology Guidelines Office   (Belgium)

^o MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

Bacillus Calmette Gu rin (BCG); Bladder cancer; Cystectomy; Diagnosis; European Association of Urology; Guidelines; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma

Indexed keywords

BCG VACCINE; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ARTICLE; BCG VACCINATION; BLADDER BIOPSY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL CLASSIFICATION; CYSTECTOMY; CYSTOSCOPY; FOLLOW UP; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMAGING; INTERMEDIATE RISK PATIENT; MEDICAL HISTORY; NON MUSCLE INVASIVE BLADDER CANCER; OPTIMAL DRUG DOSE; PAPILLOMA; PATIENT COUNSELING; PHOTODYNAMICS; PHYSICAL DISEASE BY BODY FUNCTION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; TRANSURETHRAL RESECTION; URINALYSIS; URINE CYTOLOGY; BLADDER; BLADDER TUMOR; EUROPE; INTRAVESICAL DRUG ADMINISTRATION; MEDICAL SOCIETY; PATHOLOGY; SMOOTH MUSCLE; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; UROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; CYSTOSCOPY; EUROPE; HUMANS; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 85008193429     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.05.041     Document Type: Article

References (124)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., et al. GLOBOCAN 2012 v.1.0, estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013, International Agency for Research on Cancer, Lyon, France.
2. [2] Burger, M., Catto, J.W., Dalbagni, G., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63 (2013), 234–241.
3. [3] Chavan, S., Bray, F., Lortet-Tieulent, J., Goodman, M., Jemal, A., International variations in bladder cancer incidence and mortality. Eur Urol 66 (2014), 59–73.
4. [4] Freedman, N.D., Silverman, D.T., Hollenbeck, A.R., Schatzkin, A., Abnet, C.C., Association between smoking and risk of bladder cancer among men and women. JAMA 306 (2011), 737–745.
5. [5] Rushton, L., Hutchings, S.J., Fortunato, L., et al. Occupational cancer burden in Great Britain. Br J Cancer 107:Suppl 1 (2012), S3–S7.
6. [6] Corral, R., Lewinger, J.P., Van Den Berg, D., et al. Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. Int J Cancer 135 (2014), 335–347.
7. [7] Ros, M.M., Bas Bueno-de-Mesquita, H.B., Buchner, F.L., et al. Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 128 (2011), 2695–2708.
8. [8] TNM classification of malignant tumors. Sobin, L.H., Gospodarowicz, M., Wittekind, C., (eds.) UICC International Union Against Cancer, ed 7., 2009, Wiley-Blackwell, Hoboken, NJ, 262–265.
9. [9] Mostofi, F.K., Sobin, L.H., Torloni, H., Histologic typing of urinary bladder tumors. International Histological Classification of Tumors, No. 10. 1973, World Health Organization, Geneva, Switzerland.
10. [10] Eble, J.N., Sauter, G., Epstein, J.I., Sesterhenn, I.A., (eds.) Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization classification of tumours., 2004, IARC Press, Lyon, France.
11. [11] Sylvester, R.J., van der Meijden, A., Witjes, J.A., et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66:Suppl 1 (2005), 90–107.
12. [12] Murphy, W.M., Takezawa, K., Maruniak, N.A., Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol 168 (2002), 968–972.
13. [13] May, M., Brookman-Amissah, S., Roigas, J., et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 57 (2010), 850–858.
14. [14] van Rhijn, B.W., van der Kwast, T.H., Kakiashvili, D.M., et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int 106 (2010), 206–211.
15. [15] Compérat, E., Egevad, L., Lopez-Beltran, A., et al. An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology 63 (2013), 756–766.
16. [16] Mangrud, O.M., Waalen, R., Gudlaugsson, E., et al. Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder. PLoS One, 9, 2014, e83192.
17. [17] Cho, K.S., Seo, H.K., Joung, J.Y., et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 182 (2009), 2625–2630.
18. [18] Wasco, M.J., Daignault, S., Zhang, Y., et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 70 (2007), 69–74.
19. [19] Nolte-Ernsting, C., Cowan, N., Understanding multislice CT urography techniques: many roads lead to Rome. Eur Radiol 16 (2006), 2670–2686.
20. [20] Palou, J., Rodriguez-Rubio, F., Huguet, J., et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 174 (2005), 859–861 discussion 861.
21. [21] Millan-Rodriguez, F., Chechile-Toniolo, G., Salvador-Bayarri, J., Huguet-Perez, J., Vicente-Rodriguez, J., Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol 164 (2000), 1183–1187.
22. [22] Yafi, F.A., Brimo, F., Steinberg, J., Aprikian, A.G., Tanguay, S., Kassouf, W., Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol, 33, 2015 66 e25-31.
23. [23] Tetu, B., Diagnosis of urothelial carcinoma from urine. Mod Pathol 22:Suppl 2 (2009), S53–S59.
24. [24] Raitanen, M.P., Aine, R., Rintala, E., et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 41 (2002), 284–289.
25. [25] Lokeshwar, V.B., Habuchi, T., Grossman, H.B., et al. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 66:Suppl 1 (2005), 35–63.
26. [26] Hajdinjak, T., UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 26 (2008), 646–651.
27. [27] van der Aa, M.N., Steyerberg, E.W., Bangma, C., van Rhijn, B.W., Zwarthoff, E.C., van der Kwast, T.H., Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J Urol 183 (2010), 76–80.
28. [28] Aaronson, D.S., Walsh, T.J., Smith, J.F., Davies, B.J., Hsieh, M.H., Konety, B.R., Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief?. BJU Int 104 (2009), 506–509 discussion 509–10.
29. [29] Richterstetter, M., Wullich, B., Amann, K., et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int 110 (2012), E76–E79.
30. [30] Herr, H.W., Donat, S.M., Quality control in transurethral resection of bladder tumours. BJU Int 102 (2008), 1242–1246.
31. [31] Brausi, M., Collette, L., Kurth, K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002), 523–531.
32. [32] Mariappan, P., Zachou, A., Grigor, K.M., Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57 (2010), 843–849.
33. [33] Mariappan, P., Finney, S.M., Head, E., et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 109 (2012), 1666–1673.
34. [34] Herr, H.W., Donat, S.M., Reuter, V.E., Management of low grade papillary bladder tumors. J Urol 178 (2007), 1201–1205 discussion 1205.
35. [35] Sabir, E.F., Holmäng, S., TaG1 bladder cancer: a third of all primary tumors and 80% of all recurrences can be treated in the office using local anesthesia. Urol Pract 1 (2014), 184–188.
36. [36] Gupta, N.P., Saini, A.K., Dogra, P.N., Seth, A., Kumar, R., Bipolar energy for transurethral resection of bladder tumours at low-power settings: initial experience. BJU Int 108 (2011), 553–556.
37. [37] Venkatramani, V., Panda, A., Manojkumar, R., Kekre, N.S., Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. J Urol 191 (2014), 1703–1707.
38. [38] van der Meijden, A., Oosterlinck, W., Brausi, M., Kurth, K.H., Sylvester, R., de Balincourt, C., Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 35 (1999), 267–271.
39. [39] Hara, T., Takahashi, M., Gondo, T., et al. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases. Int J Urol 16 (2009), 293–298.
40. [40] Palou, J., Sylvester, R.J., Faba, O.R., et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 62 (2012), 118–125.
41. [41] Mungan, M.U., Canda, A.E., Tuzel, E., Yorukoglu, K., Kirkali, Z., Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol 48 (2005), 760–763.
42. [42] Mowatt, G., N'Dow, J., Vale, L., et al., Aberdeen Technology Assessment Review (TAR) Group, Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care 27 (2011), 3–10.
43. [43] Neuzillet, Y., Methorst, C., Schneider, M., et al. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology. Urol Oncol 32 (2014), 1135–1140.
44. [44] Draga, R.O., Grimbergen, M.C., Kok, E.T., Jonges, T.N., van Swol, C.F., Bosch, J.L., Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. Eur Urol 57 (2010), 655–660.
45. [45] Schumacher, M.C., Holmang, S., Davidsson, T., Friedrich, B., Pedersen, J., Wiklund, N.P., Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 57 (2010), 293–299.
46. [46] Stenzl, A., Penkoff, H., Dajc-Sommerer, E., et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer 117 (2011), 938–947.
47. [47] Burger, M., Grossman, H.B., Droller, M., et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 64 (2013), 846–854.
48. [48] O'Brien, T., Ray, E., Chatterton, K., Khan, M.S., Chandra, A., Thomas, K., Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int 112 (2013), 1096–1104.
49. [49] Zheng, C., Lv, Y., Zhong, Q., Wang, R., Jiang, Q., Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int 110 (2012), E680–E687.
50. [50] Divrik, R.T., Yildirim, U., Zorlu, F., Ozen, H., The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 175 (2006), 1641–1644.
51. [51] Lazica, D.A., Roth, S., Brandt, A.S., Bottcher, S., Mathers, M.J., Ubrig, B., Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int 92 (2014), 131–135.
52. [52] Fritsche, H.M., Burger, M., Svatek, R.S., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57 (2010), 300–309.
53. [53] Sfakianos, J.P., Kim, P.H., Hakimi, A.A., Herr, H.W., The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol 191 (2014), 341–345.
54. [54] Bishr, M., Lattouf, J.B., Latour, M., Saad, F., Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J 8 (2014), E306–E310.
55. [55] Lopez-Beltran, A., Bassi, P., Pavone-Macaluso, M., Montironi, R., Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol 45 (2004), 257–266.
56. [56] Sylvester, R.J., van der Meijden, A.P., Oosterlinck, W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006), 466–475 discussion 475–7.
57. [57] Fernandez-Gomez, J., Madero, R., Solsona, E., et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model. J Urol 182 (2009), 2195–2203.
58. [58] Cambier, S., Sylvester, R.J., Collette, L., et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non–muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin. Eur Urol 69 (2016), 60–69.
59. [59] Gontero, P., Sylvester, R., Pisano, F., et al. Prognostic factors and risk groups in T1G3 non–muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67 (2015), 74–82.
60. [60] Golijanin, D., Yossepowitch, O., Beck, S.D., Sogani, P., Dalbagni, G., Carcinoma in a bladder diverticulum: presentation and treatment outcome. J Urol 170 (2003), 1761–1764.
61. [61] Palou, J., Rodriguez-Rubio, F., Millan, F., et al. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology 73 (2009), 1313–1317.
62. [62] Lamm, D.L., Carcinoma in situ. Urol Clin North Am 19 (1992), 499–508.
63. [63] Griffiths, T.R., Charlton, M., Neal, D.E., Powell, P.H., Treatment of carcinoma in situ with intravesical bacillus Calmette-Guérin without maintenance. J Urol 167 (2002), 2408–2412.
64. [64] Takenaka, A., Yamada, Y., Miyake, H., Hara, I., Fujisawa, M., Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol 15 (2008), 309–313.
65. [65] Solsona, E., Iborra, I., Dumont, R., Rubio-Briones, J., Casanova, J., Almenar, S., The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000), 685–689.
66. [66] Lammers, R.J., Witjes, W.P., Hendricksen, K., Caris, C.T., Janzing-Pastors, M.H., Witjes, J.A., Smoking status is a risk factor for recurrence after transurethral resection of non–muscle-invasive bladder cancer. Eur Urol 60 (2011), 713–720.
67. [67] Rink, M., Xylinas, E., Babjuk, M., et al. Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer. Eur Urol 62 (2012), 1204–1206.
68. [68] Sylvester, R.J., Oosterlinck, W., Holmang, S., et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?. Eur Urol 69 (2016), 231–244.
69. [69] Sylvester, R.J., Oosterlinck, W., van der Meijden, A.P., A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004), 2186–2190 quiz 2435.
70. [70] Abern, M.R., Owusu, R.A., Anderson, M.R., Rampersaud, E.N., Inman, B.A., Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw 11 (2013), 477–484.
71. [71] Perlis, N., Zlotta, A.R., Beyene, J., Finelli, A., Fleshner, N.E., Kulkarni, G.S., Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non–muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol 64 (2013), 421–430.
72. [72] Bohle, A., Jurczok, A., Ardelt, P., et al. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. J Urol 167 (2002), 357–363.
73. [73] Oddens, J.R., van der Meijden, A.P., Sylvester, R., One immediate postoperative instillation of chemotherapy in low risk Ta,T1 bladder cancer patients. Is it always safe?. Eur Urol 46 (2004), 336–338.
74. [74] Sylvester, R.J., Oosterlinck, W., Witjes, J.A., The schedule and duration of intravesical chemotherapy in patients with non–muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 53 (2008), 709–719.
75. [75] Tolley, D.A., Parmar, M.K., Grigor, K.M., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155 (1996), 1233–1238.
76. [76] Huncharek, M., McGarry, R., Kupelnick, B., Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 21 (2001), 765–769.
77. [77] Au, J.L., Badalament, R.A., Wientjes, M.G., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93 (2001), 597–604.
78. [78] Giesbers, A.A., Van Helsdingen, P.J., Kramer, A.E., Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times. Br J Urol 63 (1989), 176–179.
79. [79] Kuroda, M., Niijima, T., Kotake, T., Akaza, H., Hinotsu, S., Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer–the 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 45 (2004), 600–605.
80. [80] Lammers, R.J., Witjes, J.A., Inman, B.A., et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non–muscle-invasive bladder cancer: a systematic review. Eur Urol 60 (2011), 81–93.
81. [81] Di Stasi, S.M., Giannantoni, A., Giurioli, A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7 (2006), 43–51.
82. [82] Malmstrom, P.U., Sylvester, R.J., Crawford, D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer. Eur Urol 56 (2009), 247–256.
83. [83] Shelley, M.D., Kynaston, H., Court, J., et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88 (2001), 209–216.
84. [84] Han, R.F., Pan, J.G., Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer?. A meta-analysis of randomized trials. Urology 67 (2006), 1216–1223.
85. [85] Shelley, M.D., Wilt, T.J., Court, J., Coles, B., Kynaston, H., Mason, M.D., Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004), 485–490.
86. [86] Bohle, A., Jocham, D., Bock, P.R., Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003), 90–95.
87. [87] Duchek, M., Johansson, R., Jahnson, S., et al. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 57 (2010), 25–31.
88. [88] Jarvinen, R., Kaasinen, E., Sankila, A., Rintala, E., Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 56 (2009), 260–265.
89. [89] Sylvester, R.J., Brausi, M.A., Kirkels, W.J., et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57 (2010), 766–773.
90. [90] Bohle, A., Bock, P.R., Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004), 682–686 discussion 686–7.
91. [91] Sylvester, R.J., van der Meijden, A., Lamm, D.L., Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002), 1964–1970.
92. [92] Huncharek, M., Kupelnick, B., The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guérin immunotherapy. Am J Clin Oncol 27 (2004), 522–528.
93. [93] Oddens, J.R., Sylvester, R.J., Brausi, M.A., et al. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC Genito-Urinary Group Study 30911. Eur Urol 66 (2014), 694–701.
94. [94] Rentsch, C.A., Birkhauser, F.D., Biot, C., et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 66 (2014), 677–688.
95. [95] Sengiku, A., Ito, M., Miyazaki, Y., Sawazaki, H., Takahashi, T., Ogura, K., A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol 190 (2013), 50–54.
96. [96] Brausi, M., Oddens, J., Sylvester, R., et al. Side effects of bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC Genito-Urinary Cancers Group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65 (2014), 69–76.
97. [97] Herr, H.W., Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria. J Urol 187 (2012), 435–437.
98. [98] Rodriguez, F., Palou, J., Martinez, R., et al. Practical guideline for the management of adverse events associated with BCG installations [in Spanish]. Arch Esp Urol 61 (2008), 591–596.
99. [99] Witjes, J.A., Palou, J., Soloway, M., et al. Clinical practice recommendations for the prevention and management of intravesical therapy–associated adverse events. Eur Urol Suppl 7 (2008), 667–674.
100. [100] Lamm, D.L., Blumenstein, B.A., Crissman, J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000), 1124–1129.
101. [101] Oddens, J., Brausi, M., Sylvester, R., et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63 (2013), 462–472.
102. [102] Martinez-Pineiro, L., Portillo, J.A., Fernandez, J.M., et al. Maintenance therapy with 3-monthly bacillus Calmette-Guérin for 3 years is not superior to standard induction therapy in high-risk non–muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol 68 (2015), 256–262.
103. [103] Martinez-Pineiro, J.A., Martinez-Pineiro, L., Solsona, E., et al. Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174 (2005), 1242–1247.
104. [104] Ojea, A., Nogueira, J.L., Solsona, E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guérin (27 mg) versus very low-dose bacillus Calmette-Guérin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007), 1398–1406.
105. [105] Solsona, E., Madero, R., Chantada, V., et al. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non–muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol 67 (2015), 508–516.
106. [106] Jarvinen, R., Marttila, T., Kaasinen, E., et al. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin c followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-alpha2b instillations: prospective randomised FinnBladder-4 Study. Eur Urol 68 (2015), 611–617.
107. [107] Sylvester, R.J., van der Meijden, A.P., Witjes, J.A., Kurth, K., Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005), 86–91 discussion 92.
108. [108] Kaasinen, E., Wijkstrom, H., Malmstrom, P.U., et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 43 (2003), 637–645.
109. [109] Solsona, E., Iborra, I., Ricos, J.V., Monros, J.L., Dumont, R., Almenar, S., Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol 155 (1996), 895–899 discussion 899–900.
110. [110] Palou, J., Baniel, J., Klotz, L., et al. Urothelial carcinoma of the prostate. Urology 69:Suppl (2007), 50–61.
111. [111] Morales, A., Herr, H., Steinberg, G., et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol 193 (2015), 1135–1143.
112. [112] Yates, D.R., Brausi, M.A., Catto, J.W., et al. Treatment options available for bacillus Calmette-Guérin failure in non–muscle-invasive bladder cancer. Eur Urol 62 (2012), 1088–1096.
113. [113] Barlow, L., McKiernan, J., Sawczuk, I., Benson, M., A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU Int 104 (2009), 1098–1102.
114. [114] Nativ, O., Witjes, J.A., Hendricksen, K., et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guérin. J Urol 182 (2009), 1313–1317.
115. [115] Joudi, F.N., Smith, B.J., O'Donnell, M.A., Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006), 344–348.
116. [116] Di Lorenzo, G., Perdona, S., Damiano, R., et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116 (2010), 1893–1900.
117. [117] Turker, P., Bostrom, P.J., Wroclawski, M.L., et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int 110 (2012), 804–811.
118. [118] Shariat, S.F., Palapattu, G.S., Karakiewicz, P.I., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51 (2007), 137–149 discussion 149–51.
119. [119] Raj, G.V., Herr, H., Serio, A.M., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177 (2007), 1283–1286 discussion 1286.
120. [120] Holmang, S., Andius, P., Hedelin, H., Wester, K., Busch, C., Johansson, S.L., Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 165 (2001), 1124–1128 discussion 1128–30.
121. [121] Gofrit, O.N., Pode, D., Lazar, A., Katz, R., Shapiro, A., Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 49 (2006), 303–306 discussion 306–7.
122. [122] Mariappan, P., Smith, G., A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 173 (2005), 1108–1111.
123. [123] Soukup, V., Babjuk, M., Bellmunt, J., et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol 62 (2012), 290–302.
124. [124] Holmang, S., Strock, V., Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?. Eur Urol 61 (2012), 503–507.